Orphan Receptor Drug Discovery
This article was originally published in Start Up
Executive Summary
In a climate favoring defined clinical product opportunities, venture capitalists have had a hard time seeing the value proposition in investing in orphan nuclear receptor drug discovery. These targets likely modulate a range of diseases, but the disease associations are undetermined. Orphan receptors are also difficult targets for drug screening. Nonetheless, a handful of start-ups are taking up the drug discovery challenge.